SEC Form 4 · accession 0001562180-18-001592
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Sandor
Officer — Chief Medical Officer
Period of report
Mar 9, 2018
Accepted (ET)
Mar 9, 2018 · 5:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2018 | M | 182,191 | $3.65 | A | 373,915 | D | |
| Common StockF3 | Mar 9, 2018 | S | 44,498 | $17.70 | D | 329,417 | D | |
| Common StockF3 | Mar 9, 2018 | S | 111,518 | $17.72 | D | 217,899 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.65 | Mar 9, 2018 | M | 182,191 | D | — | Sep 22, 2024 | Common Stock | 182,191 | 379,259 | D |
Explanation of responses
- F1Includes 15,625 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
- F2These trades were made pursuant to a Rule 10b5-1 trading plan.
- F3The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- F4The option vested in four equal annual installments beginning on September 22, 2015.